國民技術(300077.SZ):內蒙古斯諾擬30億元投建年產10萬噸新能源動力電池負極材料一體化項目
格隆匯3月25日丨國民技術(300077.SZ)公佈,公司控股子公司內蒙古斯諾於2022年3月25日分別與隨州市人民政府、隨州高新技術產業開發區管理委員會簽署《投資意向書》、《投資協議書》,擬在湖北省隨州市投資建設“年產10萬噸新能源動力電池負極材料一體化項目”。
項目投資計劃:項目總投資額約30億元(最終以實際投資為準),確保固定資產投資強度150萬元/畝以上,全口徑税收強度15萬元/畝以上。
建設週期:項目建設週期為5年,項目分兩期建設。一期建設5萬噸,建設週期約8個月,自項目用地交付之日起3個月內開工建設。若無特殊情形,一期項目投產後一年內啟動二期項目建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.